EyePoint Q4 net loss $67.6M; DURAVYU wet AMD Phase 3 topline due mid-2026

EyePoint, Inc.

Net loss Q4 $67.6M ($0.81/sh) vs $41.4M ($0.64); FY net loss $232M ($3.17) vs $130.9M ($2.32).
Total net revenue Q4 $0.6M vs $11.6M, mainly from YUTIQ deferred revenue recognition.
Cash, cash equivalents & investments $306M as of Dec 31, 2025; provides runway into Q4 2027.
Both Phase 3 wet AMD trials (LUGANO, LUCIA) on track; topline data expected mid-2026. DME trials dosed.
Appointed Michael Campbell as Chief Commercial Officer for DURAVYU launch readiness.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EyePoint, Inc. reported the fourth quarter and full-year ended December 31, 2025 results: revenue $0.6 million.

Period: the fourth quarter and full-year ended December 31, 2025
Revenue: $0.6 million
Result: reported results

Exact text from the filing

million in October 2025. Exhibit 99.1 Review of Results for the Fourth Quarter Ended December 31, 2025 For the fourth quarter ended December 31, 2025, total net revenue was $0.6 million compared to $11.6 million for the quarter ended December 31, 2024. Net product revenue for the fourth quarter was $0.3 million, compared to net product revenue for the

View on SEC.gov

Browse all earnings releases →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-089856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.